Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

PA, Konstantinopoulos; S, Waggoner; GA, Vidal; M, Mita; JW, Moroney; R, Holloway; Le L, Van; JC, Sachdev; E, Chapman-Davis; G, Colon-Otero; RT, Penson; UA, Matulonis; YB, Kim; KN, Moore; EM, Swisher; A, Färkkilä; A, D'Andrea; E, Stringer-Reasor; J, Wang; N, Buerstatte; S, Arora; JR, Graham; D, Bobilev; BJ, Dezube; P, Munster

doi:10.1001/jamaoncol.2019.1048

Public

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

Shared by NobleBlocks on Aug 1, 2019 • 12:00 AM UTC

Authors:

Konstantinopoulos PA

Waggoner S

Vidal GA

Abstract

<h4>Importance</h4>Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited.<h4>Objective</h4>To evaluate the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor niraparib combined with pembroliz...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!